Martínez Isabel M, Morales Inmaculada, García-Pino Guadalupe, Campillo José E, Tormo María A
Departamento de Fisiología, Facultad de Medicina, Universidad de Extremadura, Badajoz, Spain.
Exp Diabesity Res. 2003 Apr-Jun;4(2):119-23. doi: 10.1155/EDR.2003.119.
Diabetes in humans and in experimental animals produces changes in the function and structure of the small intestine. The authors determined the activity of intestinal disaccharidases (maltase and sucrase) and of 6-phosphofructo-1-kinase (PFK-1) in enterocytes isolated from the small intestine of male Wistar rats (2.5 to 3 months old) with experimental nonobese type 2 diabetes, induced by streptozotocin (STZ) injection on the day of birth (n0-STZ) or on the 5th day of life (n5-STZ), with different degrees of hyperglycemia and insulinemia (n0-STZ and n5-STZ models). The glycemia (mmol/L) of the diabetic rats (n0-STZ: 8.77 +/- 0.47; n5-STZ: 20.83 +/- 0.63) was higher (P <.01) than that of the nondiabetic (ND) rats (5.99 +/- 0.63); on the contrary, the insulinemia (ng/mL) was significantly lower in both n0-STZ (1.74 +/- 0.53; P <.05) and n5-STZ (1.12 +/- 0.44; P <.01) diabetic rats than in normal rats (3.77 +/- 0.22). The sucrase and maltase activities (U/g protein) in diabetic rats (n0-STZ: 89 +/- 9 and 266 +/- 12; n5-STZ: 142 +/- 23 and 451 +/- 57) were significantly higher than those in the ND group (66 +/- 5 and 228 +/- 22). The PFK-1 activities (mU/mg protein) in the diabetic models (n0-STZ: 14.89 +/- 1.51; n5-STZ: 13.35 +/- 3.12) were significantly lower (P <.05) than in ND rats (20.54 +/- 2.83). The data demonstrated enzymatic alterations in enterocytes isolated from the small intestine of n0-STZ rats that are greater (P <.05) than in the more hyperglycemic and hypoinsulinemic n5-STZ animals. The results also show that nonobese type 2-like diabetes in the rat produces modifications that favor an increase in glucose absorption rates.
人类和实验动物的糖尿病会导致小肠功能和结构发生变化。作者测定了从雄性Wistar大鼠(2.5至3月龄)小肠分离的肠上皮细胞中肠双糖酶(麦芽糖酶和蔗糖酶)以及6-磷酸果糖-1-激酶(PFK-1)的活性,这些大鼠通过在出生当天(n0-STZ)或出生后第5天(n5-STZ)注射链脲佐菌素(STZ)诱导产生实验性非肥胖型2型糖尿病,具有不同程度的高血糖和胰岛素血症(n0-STZ和n5-STZ模型)。糖尿病大鼠(n0-STZ:8.77±0.47;n5-STZ:20.83±0.63)的血糖(mmol/L)高于非糖尿病(ND)大鼠(5.99±0.63)(P<.01);相反,n0-STZ(1.74±0.53;P<.05)和n5-STZ(1.12±0.44;P<.01)糖尿病大鼠的胰岛素血症(ng/mL)均显著低于正常大鼠(3.77±0.22)。糖尿病大鼠(n0-STZ:89±9和266±12;n5-STZ:142±23和451±57)的蔗糖酶和麦芽糖酶活性(U/g蛋白)显著高于ND组(66±5和228±22)。糖尿病模型(n0-STZ:14.89±1.51;n5-STZ:13.35±3.12)中的PFK-1活性显著低于ND大鼠(20.54±2.83)(P<.05)。数据表明,从n0-STZ大鼠小肠分离的肠上皮细胞中的酶改变比高血糖和低胰岛素血症更严重的n5-STZ动物更大(P<.05)。结果还表明,大鼠中的非肥胖型2型糖尿病样疾病会产生有利于提高葡萄糖吸收率的改变。